^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Small Intestinal Carcinoma

    Apply
    Nivolumab and Ipilimumab in Treating Patients With Rare Tumors (SWOG S1609) (NCT02834013)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    06/13/2024
    Initiation :
    01/30/2017
    Primary completion :
    05/01/2026
    Completion :
    05/01/2026
    CD4
    |
    PD-L1 overexpression • PD-L1 amplification
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • MK-1088
    A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers (NCT04708470)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    06/10/2024
    Initiation :
    10/05/2021
    Primary completion :
    06/30/2024
    Completion :
    12/31/2025
    PD-L1 • CD4
    |
    PD-L1 negative
    |
    Jingzhuda (entinostat) • bintrafusp alfa (M7824) • PDS01ADC
    Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas (NCT05565417)
    Phase 1/2
    Immunitas Therapeutics
    Recruiting
    Last update posted :
    05/03/2024
    Initiation :
    11/28/2022
    Primary completion :
    04/01/2025
    Completion :
    04/01/2025
    KRAS • BRAF • ALK • PIK3CA • MET • MSI
    |
    BRAF V600E • KRAS mutation • HR positive • MSI-H/dMMR • HER-2 overexpression • PIK3CA mutation
    |
    Fruzaqla (fruquintinib) • IMT-009
    Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders (NCT04729322)
    Phase 2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    05/02/2024
    Initiation :
    02/22/2021
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    MSI • MLH1 • MSH6 • MSH2 • CEACAM5
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab)
    Quebec Pancreas Cancer Study (QPCS) (NCT04104230)
    Phase N/A
    George Zogopoulos
    Recruiting
    Last update posted :
    04/17/2024
    Initiation :
    03/12/2012
    Primary completion :
    01/01/2025
    Completion :
    01/01/2025
    BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • EPCAM • PRSS1
    |
    ATM mutation • STK11 mutation • PALB2 mutation • CDKN2A mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation
    Testing Obeticholic Acid for Familial Adenomatous Polyposis (NCT05223036)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    04/16/2024
    Initiation :
    01/19/2023
    Primary completion :
    01/31/2026
    Completion :
    02/21/2026
    APC
    |
    APC mutation
    Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors (NCI-2018-01399) (NCT03108131)
    Phase 2
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    04/05/2024
    Initiation :
    04/07/2017
    Primary completion :
    04/02/2024
    Completion :
    04/02/2024
    PD-L1
    |
    PD-L1 expression
    |
    Tecentriq (atezolizumab) • Cotellic (cobimetinib)
    Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy (NCT02381561)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    03/07/2024
    Initiation :
    02/01/2016
    Primary completion :
    11/08/2018
    Completion :
    03/05/2025
    CD4
    |
    ropidoxuridine (IPdR)
    Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma (NCT01815749)
    Phase 1
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    01/04/2024
    Initiation :
    10/08/2013
    Primary completion :
    01/09/2018
    Completion :
    09/27/2024
    EGFR • CD34
    Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery (ZEBRA) (NCT02949219)
    Phase 2
    Academic and Community Cancer Research United
    Active, not recruiting
    Last update posted :
    12/28/2023
    Initiation :
    03/24/2017
    Primary completion :
    01/31/2019
    Completion :
    03/31/2024
    PD-L1 • MSI
    |
    Keytruda (pembrolizumab)
    Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers (ARM-GI) (NCT04221893)
    Phase N/A
    University of California, San Francisco
    Recruiting
    Last update posted :
    11/17/2023
    Initiation :
    08/07/2020
    Primary completion :
    12/31/2024
    Completion :
    11/30/2026
    MSI • PD-1
    Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers (NCT04491955)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    11/14/2023
    Initiation :
    09/22/2020
    Primary completion :
    10/25/2022
    Completion :
    01/31/2026
    CEACAM5 • CD4
    |
    bintrafusp alfa (M7824) • Anktiva (nogapendekin alfa inbakicept-pmln) • PDS01ADC • Panvac-VF (falimarev/inalimarev)
    Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies (NCT04566393)
    Phase N/A
    xCures
    Available
    Last update posted :
    08/21/2023
    BRAF • NRAS • HRAS • MAPK1
    |
    BRAF mutation • ER mutation • HRAS mutation
    |
    ulixertinib (BVD-523)
    Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas (NCT02213913)
    Phase 1/2
    University of Chicago
    Active, not recruiting
    Last update posted :
    04/28/2023
    Initiation :
    07/29/2014
    Primary completion :
    07/29/2023
    Completion :
    07/29/2023
    MYC • BCL2 • CD20 • BCL6 • IRF4 • MME
    |
    BCL2 positive
    |
    Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • melphalan • cyclophosphamide intravenous
    JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation (NCT05194995)
    Phase 1/2
    Jacobio Pharmaceuticals Co., Ltd.
    Recruiting
    Last update posted :
    03/10/2023
    Initiation :
    02/17/2022
    Primary completion :
    12/01/2023
    Completion :
    01/01/2026
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Erbitux (cetuximab) • glecirasib (JAB-21822)
    Videocapsule Endoscopy in Lynch Syndrome (NCT05704010)
    Phase N/A
    San Raffaele University
    Recruiting
    Last update posted :
    01/30/2023
    Initiation :
    11/01/2018
    Primary completion :
    12/31/2025
    Completion :
    12/31/2026
    MLH1 • MSH6 • MSH2 • EPCAM
    Nutrition in Gastrointestinal Tumors (NutriGIT) (NCT04476082)
    Phase N/A
    University Medicine Greifswald
    Completed
    Last update posted :
    01/24/2023
    Initiation :
    06/25/2020
    Primary completion :
    12/06/2022
    Completion :
    12/06/2022
    CRP
    Programs To Support You During Chemotherapy (PRO-YOU) (NCT02489422)
    Phase N/A
    Wake Forest University Health Sciences
    Completed
    Last update posted :
    10/14/2022
    Initiation :
    08/01/2016
    Primary completion :
    01/01/2020
    Completion :
    01/01/2020
    IL6 • TNFA • TNFRSF1A
    Robotic Versus Open Pancreaticoduodenectomy for Pancreatic and Periampullary Tumors (PORTAL) (NCT04400357)
    Phase 3
    Ruijin Hospital
    Recruiting
    Last update posted :
    05/03/2022
    Initiation :
    06/15/2020
    Primary completion :
    10/07/2022
    Completion :
    11/30/2022
    IL6 • CRP
    A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours (NETTER-1) (NCT01578239)
    Phase 3
    Advanced Accelerator Applications
    Completed
    Last update posted :
    04/04/2022
    Initiation :
    09/06/2012
    Primary completion :
    07/31/2015
    Completion :
    01/18/2021
    SSTR
    |
    Lutathera (lutetium Lu 177 dotatate) • octreotide acetate
    CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater (NCT01202409)
    Phase 2
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    02/21/2020
    Initiation :
    11/02/2010
    Primary completion :
    07/03/2018
    Completion :
    07/03/2018
    KRAS
    |
    KRAS mutation • KRAS wild-type • RAS wild-type
    |
    Vectibix (panitumumab)
    Endoscopic Evaluation of Duodenal Polyposis in Patients With Familial Adenomatous Polyposis (FAP) (NCT03346980)
    Phase N/A
    Copenhagen University Hospital, Hvidovre
    Completed
    Last update posted :
    02/13/2020
    Initiation :
    12/01/2017
    Primary completion :
    01/23/2020
    Completion :
    01/23/2020
    APC
    |
    APC mutation
    Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer (NCT00089011)
    Phase 2
    Fred Hutchinson Cancer Center
    Completed
    Last update posted :
    01/29/2020
    Initiation :
    04/01/2004
    Primary completion :
    03/01/2014
    Completion :
    07/01/2018
    HLA-DRB1 • HLA-B • HLA-C
    |
    fludarabine IV
    Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas (NCT01730586)
    Phase 2
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    01/18/2020
    Initiation :
    11/01/2012
    Primary completion :
    08/01/2016
    Completion :
    08/01/2016
    KRAS • MLH1
    |
    KRAS wild-type • RAS wild-type
    |
    albumin-bound paclitaxel
    Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies (NCT01839916)
    Phase 2
    University of Chicago
    Completed
    Last update posted :
    08/07/2019
    Initiation :
    04/04/2013
    Primary completion :
    08/01/2018
    Completion :
    08/01/2018
    HLA-DRB1
    Sensitivity and Specificity of NGS in Detecting bMSI in Patients With Gastric, Duodenal and Small Intestinal Cancer (NCT03915171)
    Phase N/A
    China Medical University, China
    Unknown status
    Last update posted :
    04/16/2019
    Initiation :
    03/01/2019
    Primary completion :
    12/01/2019
    Completion :
    06/01/2020
    MSI
    |
    MSI-H/dMMR
    Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies (NCT01789255)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    07/24/2018
    Initiation :
    06/01/2013
    Primary completion :
    03/01/2014
    Completion :
    03/01/2014
    IL6 • HLA-DRB1 • HLA-B • HLA-C
    |
    Zolinza (vorinostat) • cyclosporin A microemulsion • methotrexate IV
    Immune Reconstitution After Autologous Hematopoietic Stem Cell Transpl for High-Risk Lymphoma (NCT00569309)
    Phase N/A
    Ohio State University Comprehensive Cancer Center
    Completed
    Last update posted :
    03/12/2018
    Initiation :
    12/12/2007
    Primary completion :
    07/29/2011
    Completion :
    07/29/2011
    ALK • IL10 • TGFB1
    |
    ALK negative
    Pancreaticoduodenectomy With or Without Preoperative Hyperbaric Oxygen Therapy (HBOT) (NCT02575014)
    Phase N/A
    Florida Hospital Tampa Bay Division
    Enrolling by invitation
    Last update posted :
    02/07/2018
    Initiation :
    10/01/2013
    Primary completion :
    12/01/2018
    Completion :
    12/01/2022
    IL6 • CEACAM5 • IL2 • IL10 • CA 19-9
    Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma (NCT00867529)
    Phase 2
    Fred Hutchinson Cancer Center
    Completed
    Last update posted :
    01/02/2018
    Initiation :
    02/01/2009
    Primary completion :
    03/01/2015
    Completion :
    03/26/2015
    CD20
    |
    CD20 expression
    |
    Rituxan (rituximab)
    Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer (NCT00433550)
    Phase 2
    Alliance for Clinical Trials in Oncology
    Completed
    Last update posted :
    08/24/2017
    Initiation :
    05/01/2007
    Primary completion :
    12/01/2014
    Completion :
    05/01/2016
    UGT1A1
    |
    UGT1A1*1*1
    |
    capecitabine • oxaliplatin • irinotecan
    Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer (NCT00987766)
    Phase 1
    Vanderbilt-Ingram Cancer Center
    Completed
    Last update posted :
    07/02/2017
    Initiation :
    11/01/2009
    Primary completion :
    07/01/2013
    Completion :
    10/01/2016
    KRAS • CDH1 • VIM
    |
    erlotinib • gemcitabine • oxaliplatin
    Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer (NCT00118352)
    Phase 2
    Fred Hutchinson Cancer Center
    Completed
    Last update posted :
    05/30/2017
    Initiation :
    03/01/2005
    Primary completion :
    07/01/2010
    Completion :
    05/26/2015
    HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C
    |
    Campath (alemtuzumab) • fludarabine IV • cyclosporin A microemulsion
    Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer (NCT00654160)
    Phase 1
    Mayo Clinic
    Completed
    Last update posted :
    05/25/2017
    Initiation :
    06/01/2008
    Primary completion :
    11/01/2010
    Completion :
    12/03/2012
    UGT1A1
    |
    UGT1A1*1*1
    |
    5-fluorouracil • irinotecan • leucovorin calcium
    Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma (NCT01110135)
    Phase 2
    University of Washington
    Completed
    Last update posted :
    05/24/2017
    Initiation :
    08/01/2010
    Primary completion :
    11/01/2013
    CD34
    |
    cisplatin • etoposide IV • dexamethasone • bendamustine • Neupogen (filgrastim)
    Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer (NCT00112593)
    Phase N/A
    Fred Hutchinson Cancer Center
    Completed
    Last update posted :
    05/24/2017
    Initiation :
    11/01/1999
    Primary completion :
    11/01/2014
    HLA-DRB1 • CD4 • HLA-DQB1 • HLA-B • HLA-C
    |
    fludarabine IV • cyclosporin A microemulsion
    Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies (NCT01427881)
    Phase 2
    Fred Hutchinson Cancer Center
    Completed
    Last update posted :
    05/19/2017
    Initiation :
    09/01/2011
    Primary completion :
    06/01/2014
    Completion :
    07/01/2015
    FLT3 • KIT • NPM1 • HLA-DRB1 • HLA-B • HLA-C
    |
    MLL rearrangement • MLL rearrangement
    |
    cyclophosphamide • fludarabine IV • busulfan • cyclosporin A microemulsion • cyclophosphamide intravenous
    Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer (NCT00049504)
    Phase 2
    Fred Hutchinson Cancer Center
    Completed
    Last update posted :
    05/17/2017
    Initiation :
    01/01/2002
    Primary completion :
    03/01/2011
    Completion :
    02/01/2014
    CD8 • HLA-DRB1 • PTPRC • NCAM1 • HLA-B • HLA-C • NCR1
    |
    CD8 expression • Chr del(5q) • CD4 expression
    |
    cyclophosphamide • fludarabine IV • cyclophosphamide intravenous